Sage Therapeutics pricing for Zulresso at a premium to Piper Jaffray estimate

Piper Jaffray analyst Danielle Brill, who maintained an Overweight rating and $206 price target on Sage Therapeutics shares, noted that the announced plans to price Zulresso at $25,000-$35,000 per course — should it be approved on its December 19 PDUFA date — which is at a premium to Piper’s estimated net pricing of $15,000. Brill also noted that the drug’s sales force has been hired, which includes ~130 reps, and ~50 patient support/access personnel, and she is awaiting final commercial details following PDUFA announcement.
https://thefly.com/landingPageNews.php?id=2818641